These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 25609064

  • 1. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.
    Clin Cancer Res; 2015 Jul 15; 21(14):3140-8. PubMed ID: 25609064
    [Abstract] [Full Text] [Related]

  • 2. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandalà M.
    Eur J Cancer; 2017 Jun 15; 78():70-81. PubMed ID: 28412591
    [Abstract] [Full Text] [Related]

  • 3. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M.
    Ann Oncol; 2015 Sep 15; 26(9):1980-1987. PubMed ID: 26037795
    [Abstract] [Full Text] [Related]

  • 4. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K, Okoye S, Herbst R, Ulrich J, Terheyden P, Pföhler C, Utikal JS, Kreuter A, Mohr P, Dippel E, Satzger I, Sucker A, Schadendorf D, Ugurel S, Gutzmer R.
    Eur J Cancer; 2018 Jan 15; 88():67-76. PubMed ID: 29195116
    [Abstract] [Full Text] [Related]

  • 5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 15; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 6. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
    Kakavand H, Rawson RV, Pupo GM, Yang JYH, Menzies AM, Carlino MS, Kefford RF, Howle JR, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, Rizos H.
    Clin Cancer Res; 2017 Oct 15; 23(20):6054-6061. PubMed ID: 28724663
    [Abstract] [Full Text] [Related]

  • 7. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
    Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA.
    Clin Cancer Res; 2012 Mar 01; 18(5):1386-94. PubMed ID: 22156613
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.
    Cancer; 2015 Nov 01; 121(21):3826-35. PubMed ID: 26218930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, Bartsch R, Höller C, Preusser M.
    Histopathology; 2015 Jan 01; 66(2):289-99. PubMed ID: 25314639
    [Abstract] [Full Text] [Related]

  • 14. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
    Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D, DeCOG.
    Ann Oncol; 2014 Mar 01; 25(3):747-753. PubMed ID: 24504444
    [Abstract] [Full Text] [Related]

  • 15. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.
    J Am Acad Dermatol; 2014 Dec 01; 71(6):1102-1109.e1. PubMed ID: 25440439
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH, Kong SY, Ro JY, Kwon Y, Kang JH, Mo HJ, Jung SY, Lee S, Lee KS, Kang HS, Lee E, Joo J, Ro J.
    Clin Breast Cancer; 2016 Feb 01; 16(1):51-8. PubMed ID: 26364145
    [Abstract] [Full Text] [Related]

  • 17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.
    Sci Transl Med; 2015 Mar 18; 7(279):279ra41. PubMed ID: 25787767
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH.
    Lung Cancer; 2015 Apr 18; 88(1):24-33. PubMed ID: 25662388
    [Abstract] [Full Text] [Related]

  • 20. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A.
    Clin Cancer Res; 2015 Apr 01; 21(7):1639-51. PubMed ID: 25589619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.